• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, July 24, 2020

Article

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care® (AJMC®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.

An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.

Related Videos
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD
Amir Fathi, MD, Massachusetts General Hospital
Kelley L. Julian, PharmD, BCOP
Dr David Kuter
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Dr Brian Koffman
Paula Rodríguez-Otero, MD, PhD, Cancer Center Clínica Universidad de Navarra
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.